Tata Motors' total sales (including exports) of Tata commercial and passenger vehicles fell 34% to 33,892 vehicles in April 2014 over April 2013. The company's domestic sales of Tata commercial and passenger vehicles declined 36% to 30,670 units in April 2014 over April 2013. The company's sales of commercial vehicles in the domestic market fell 36% to 23,229 units in April 2014 over April 2013. LCV sales fell 43% to 14,804 units in April 2014 over April 2013, while M&HCV sales declined 16% to 8,425 units in April 2014 over April 2013. Sales of passenger vehicles were lower by 36% to 7,441 units in April 2014 over April 2013. Sales of the Nano/ Indica/ Indigo range were down 37% to 5,653 units in April 2014 over April 2013. The Sumo/ Safari/ Aria/ Venture range sales fell 33% to 1,788 units in April 2014 over April 2013. The company's sales from exports registered a decline of 10% to 3,222 units in April 2014 over April 2013. Tata Motors announced sales figures after market hours on Friday, 2 May 2014.
Ashok Leyland reported 21% decline in total sales to 5897 units in April 2014 over April 2013. Total sales of medium and heavy commercial vehicle (M&HCV) fell 14% to 4523 units in April 2014 over April 2013. Total sales of light commercial vehicles (LCV) declined 39% to 1374 units in April 2014 over April 2013.
Canara Bank, Emami and Piramal Enterprises will announce their January-March 2014 quarter results today, 5 May 2014.
Reliance Communications' (RCom) consolidated net profit fell 48.51% to Rs 156 crore on 4.78% decline in total income to Rs 5671 crore in Q4 March 2014 over Q4 March 2013. The company's consolidated net profit rose 55.8% to Rs 1047 crore on 2.5% rise in revenues to Rs 22321 crore in the year ended 31 March 2014 (FY 2014) over FY 2013. The company announced Q4 result after market hours on Friday, 2 May 2014.
The company's consolidated net profit rose 43.9% to Rs 156 crore on 5% rise in revenue at Rs 5671 crore in Q4 March 2014 over Q3 December 2013. Earnings before interest, tax, depreciation and amortization (EBITDA) gained 0.4% to Rs 1852 crore in Q4 March 2014 over Q3 December 2013. EBITDA margin stood at 32.7% in Q4 March 2014, amongst the highest in the industry, with strong contribution from both India and Global businesses.
Revenue of India operations rose 0.3% to Rs 4649 crore in Q4 March 2014 over Q3 December 2013. EBITDA of India operations rose 3.2% to Rs 1659 crore in Q4 March 2014 over Q3 December 2013
Revenue of global operations rose 15.7% to Rs 1261 crore in Q4 March 2014 over Q3 December 2013. EBIDTA of global operations stood at Rs193 crore in Q4 March 2014, EBIDTA margin stood at 15.3% in Q4 March 2014.
More From This Section
RCom generated operational cash flow (EBITDA) of Rs. 1852 crore in Q4 March 2014, paid net finance charges of Rs 907 crore and invested Rs 467 crore on capex during the quarter. It remains free cash flow (FCF) positive and this is expected to continue, company said.
Among its key performance indicators (KPIs), revenue per minute (RPM) was stable at 43.2 paisa. Voice RPM at 33.0 paisa. During the year, the company has significantly improved RPM with tariff hikes and strong focus on paid and profitable Minutes.
Average revenue per user (ARPU) rose 2.4% at Rs 128 in Q4 March 2014 over Q3 December 2013. The total MOUs was up by 0.4% at 102.3 billion in Q4 March 2014 over Q3 December 2013.
The total data traffic was up 20.5% to 50,251 million MB in Q4 March 2014 over Q3 December 2013. The traffic has increased due to increase in data subscribers and higher data usage per customer
The total data customer base has grown 3.3% to 37.4 million in Q4 March 2014 over Q3 December 2013, including 12.9 million 3G customers in Q4
Reliance Capital's consolidated net profit rose 1% to Rs 267 crore on 9% growth in total income to Rs 1848 crore in Q4 March 2014 over Q4 March 2013. The result was announced after market hours on Friday, 2 May 2014.
Reliance Capital's consolidated net profit rose 59% to Rs 747 crore on 14% growth in total income to Rs 7544 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (excluding one-time capital gains on stake sale in RCAM in FY 2013). Reliance Capital's net worth rose 4% year-on-year (YoY) to Rs 12483 crore as of 31 March 2014.
The company had a net debt equity ratio of 1.82 as on 31 March 2014. It continues to enjoy the highest ratings of 'A1+' by ICRA and CRISIL, for its short term borrowings program and 'CARE AAA' by CARE for its long term borrowing program, Reliance Capital said in a statement. As on 31 March 2014, the total assets of the company stood at Rs 45528 crore, an increase of 12%. Reliance Capital said the company has not raised any fixed deposits from the public.
Grasim Industries' consolidated net profit after minority interest (before exceptional item) rose 11% to Rs 679 crore on 10% growth in revenue to Rs 8419 crore in Q4 March 2014 over Q4 March 2013. The Q4 result was announced after market hours on Friday, 2 May 2014.
There was an exceptional gain of Rs 204 crore on the sale of Grasim's stake in Alexandria Carbon Black and Thai Carbon Black in Q4 March 2013.
Grasim Industries' consolidated net profit (before exceptional item) declined 17.12% to Rs 2072 crore on 5% growth in revenue to Rs 29324 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (FY 2013).
Despite the prevailing economic slowdown during the year, volumes have been augmented in all the businesses viz. VSF, Chemical and Cement, driven by the commissioning of new capacities, Grasim Industries said. An overcapacity in the VSF business globally and Cement business in India has impacted the realisations and profitability, the company said in a statement.
With regard to its future business outlook, Grasim Industries said that in the VSF sector, margins are likely to remain under pressure in the near term due to overcapacity in China. The slowdown of new capacity additions in China should lead to improvement in industry utilization, the company said. With additional capacity coming on stream, the company is well equipped to further consolidate its leadership position in the industry, it added. In Cement, the demand growth for the industry should gradually recover to 8% on improvement in the economic environment, Grasim Industries said in a statement.
Grasim Industries' board of directors at its meeting held on Friday, 2 May 2014, recommended dividend of Rs 21 per share for FY 2014.
Deepak Nitrite's net profit surged 68.25% to Rs 15.85 crore on 16.13% growth in total income from operations to Rs 360.61 crore in Q4 March 2014 over Q4 March 2013. The result was announced after market hours on Friday, 2 May 2014.
Deepak Nitrite's net profit rose 1.32% to Rs 38.32 crore on 24.54% growth in total income from operations to Rs 1269.62 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (FY 2013).
Deepak Nitrite's board of directors at its meeting held on Friday, 2 May 2014, approved 5-for-1 stock split. The board also approved issue of bonus shares in the ratio of 1:1. Also, the board approved payment of dividend of Rs 10 per share for FY 2014.
Pfizer's net profit fell 3.66% to Rs 56.03 crore on 2.46% decline in total income from operations to Rs 274.48 crore in Q4 March 2014 over Q4 March 2013. Net profit fell 56.11% to Rs 220.85 crore on 6% rise in total income from operations to Rs 1111.80 crore in the year ended March 2014 over the year ended March 2013.
Pfizer's revenue for the quarter was Rs 251.69 crore as compared to Rs 252.19 crore in the same period last year. The revenue for the year was Rs 1004.27 crore as compared to Rs 947.98 crore last year.
Excluding the transitional support for sales of certain animal health products, the pharmaceutical revenue for the quarter registered a growth of 6% to Rs 251.69 crore as compared to Rs 237.24 crore in the same period last year. Similarly the revenue for the year registered a growth of 5% to Rs 961.80 crore as compare to Rs 915.06 crore last year. The profit before tax and exceptional items for the year grew by 21% to Rs 339.58 crore from Rs 279.65 crore last year, Pfizer said in a statement.
Sun Pharmaceutical Industries (Sun Pharma) after market hours on Friday, 2 May 2014, announced that, as a part of its manufacturing consolidation in the US, it has notified the Workforce Development Agency for the State of Michigan regarding its decision to cease manufacturing operations and close the Detroit (Caraco Pharmaceutical Laboratories,Ltd.) facility located at Elijah McCoy Detroit, Ml, USA. The company has provided the requisite advance written notice of the facility closure to the employee union and all affected employees, Sun Pharma said in a statement.
Sun Pharma said it has ensured that the impacted employees get compensated with more than their regular entitlement under the severance package. They will also receive other support services including outplacement assistance, the company added. The rest of the employees are continuing through mutually consented arrangements, Sun Pharma said in a statement.
Sun Pharma said it has undertaken necessary measures to ensure business continuity of the products being manufactured at this facility. The manufacturing of these products is being transferred to other units and all necessary steps have been taken to avoid market shortage, the company said. Sun Pharma said it expects a negligible impact of this development on its FY 2015 consolidated revenues.
Separately, Sun Pharma after market hours on Friday, 2 May 2014 in a clarification with regard to news item titled "Sun-Ranbaxy merger runs into legal wrangle" said that it was neither served the notice of the hearing nor it was aware of such hearing being held nor it is served with the copy of the court order, so the question of submission of court order to the exchanges doe not arise, Sun Pharma said.
Ranbaxy Laboratories after market hours on Friday, 2 May 2014 in a clarification with regard to news item "Sun-Ranbaxy merger runs into legal wrangle" said that the company has neither received any Notice nor appeared/represented before the Hon'ble High Court in regard to aforesaid Court case. Further, the company has also not been served the Order of the Hon'ble Court, Ranbaxy Laboratories said.
AstraZeneca Pharma India said that its board will meet on 5 May 2014, to consider seeking approval of shareholders of the company through postal ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, promoter of the company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.
Indraprastha Gas will be in focus on reports the company on Friday, 2 May 2014, raised prices of CNG (gas used as automotive fuel) by Rs 2.95 per kg and PNG (piped gas in kitchens) by Re 1 citing rise in input costs.
Power Finance Corporation announced after market hours on Friday, 2 May 2014 that the board of directors of the company at its meeting held on 2 May 2014, has approved conduct of postal ballot seeking approval of the shareholders on the slew of proposals including raising of resources through private placement of non-convertible debentures, enhancement of the borrowing power for the purpose of business of the company, authorization to the board of directors for mortgaging and/or creating charge on the assets of the company for securing borrowings for the purpose of the company and .fixation of 9 May 2014 as the cut-off date for reckoning voting rights of the shareholders.
Financial Technologies (India) (FTIL) said that its board met on 2 May 2014 and took note on the progress on the divestment of 24% stake in MCX, since the last board meeting held on 25 April 2014. The board was to deliberate on the final bidder at board meeting held on 2 May 2014.
However, in the light of developments of MCX releasing executive summary of the Report of special audit conducted by PWC, some of the bidders have requested for the full report and also further information about MCX. Their request has been sent to MCX by the Company's Merchant Bankers. In view of this, the bidders have not submitted the binding bids.
Accordingly, the board has decided to meet again on 10 May 2014 to review the progress on the divestment of 24% stake in MCX, FTIL said in a statement.
R Systems International said that its board will meet on 10 May 2014 to discuss and review business operations of the company.
Powered by Capital Market - Live News